"Sterile Bioprocess Filtration Market Global Report 2026" has been added to ResearchAndMarkets.com's offering.
The global sterile bioprocess filtration market is experiencing rapid growth, driven by rising biopharmaceutical production, expanding pharmaceutical manufacturing capacity and increased regulatory focus on product sterility and safety. The market is projected to grow from $4.59 Billion in 2025 to $5.53 Billion in 2026, representing a compound annual growth rate (CAGR) of 20.6%.
Historical market growth has been supported by increasing demand for biologics and vaccines, the expansion of pharmaceutical manufacturing infrastructure and the gradual adoption of high-efficiency sterile filtration systems. Manufacturers have continued to strengthen contamination-control processes as regulators and healthcare organizations place greater emphasis on the safety, purity and consistency of biopharmaceutical products.
The sterile bioprocess filtration market is forecast to reach $11.52 Billion by 2030, expanding at a CAGR of 20.1%. Growth during the forecast period is expected to be supported by rising demand for cell and gene therapy manufacturing, increased use of single-use and disposable filtration systems, and the integration of automated bioprocessing technologies. Expanding biologics pipelines, growth in contract manufacturing and stricter global standards for sterile production are also expected to create significant opportunities for filtration technology providers.
Key sterile bioprocess filtration market trends include the broader adoption of single-use filtration systems across bioprocessing workflows and growing demand for high-throughput membrane filtration in biologics purification. Pharmaceutical manufacturers are also integrating advanced filtration into aseptic fill-finish operations, implementing continuous bioprocess filtration for scalable production and adopting automated filter integrity testing and validation systems. These technologies can help improve operational efficiency, support process consistency and reduce contamination risks.
Rising demand for biopharmaceuticals remains a major market growth driver. The increasing prevalence of chronic diseases, combined with the adoption of targeted biologic therapies, is accelerating demand for monoclonal antibodies, vaccines, recombinant proteins and biosimilars. Sterile bioprocess filtration supports contamination control, product purity and efficient downstream processing throughout biopharmaceutical manufacturing.
Regulatory activity also demonstrates the continued expansion of the biologics sector. In January 2025, the U.S. Food and Drug Administration reported that its Center for Drug Evaluation and Research approved a record 18 biosimilars across eight reference products during 2024. This represented the highest annual biosimilar approval total recorded by the agency and highlighted the growing need for reliable sterile filtration capacity across biologics production environments.
Market participants are investing in advanced virus-removal filtration technologies to improve contamination control, strengthen biologic safety and increase manufacturing efficiency. In October 2024, Asahi Kasei Medical Co. Ltd. introduced Planova FG1, a next-generation virus-removal filter for biopharmaceutical manufacturing. The solution offers higher filtration flux, dependable viral clearance performance and compatibility with sterilization-in-place processes. It is designed to support scalable biologics production while helping manufacturers meet demanding safety and process-performance requirements.
Markets and Acquisitions
Strategic acquisitions are also reshaping the competitive environment. In September 2025, Thermo Fisher Scientific Inc. acquired Solventum's Purification and Filtration business for approximately USD 4.1 Billion. The transaction is intended to enhance Thermo Fisher Scientific's purification and filtration capabilities, broaden its technology portfolio and strengthen its support for sterile, high-efficiency biologics manufacturing.
North America dominated the sterile bioprocess filtration market in 2025, supported by its established biopharmaceutical industry, advanced manufacturing infrastructure and strong regulatory environment. Asia-Pacific is expected to be the fastest-growing region during the forecast period as biologics production capacity and pharmaceutical investment increase. The market analysis covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa, including Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy and Spain.
